Angiogenesi
Gli inibitori dell'angiogenesi sono composti che interferiscono con la formazione di nuovi vasi sanguigni, un processo cruciale nella crescita e metastasi del cancro. Inibendo l'angiogenesi, questi composti possono limitare l'apporto di sangue ai tumori, rallentandone o arrestando la crescita. Gli inibitori dell'angiogenesi sono fondamentali nella ricerca sul cancro e nello sviluppo terapeutico, offrendo approfondimenti sui meccanismi di progressione tumorale e potenziali trattamenti per il cancro e altre malattie legate all'angiogenesi. Presso CymitQuimica, offriamo un'ampia gamma di inibitori dell'angiogenesi di alta qualità per supportare le tue ricerche in oncologia e biologia vascolare.
Sottocategorie di "Angiogenesi"
- BTK(159 prodotti)
- Bcr-Abl(115 prodotti)
- EGFR(594 prodotti)
- FAK(72 prodotti)
- FLT(90 prodotti)
- Recettore del fattore di crescita dei fibroblasti (FGFR)(182 prodotti)
- JAK(246 prodotti)
- PDGFR(126 prodotti)
- RAAS(90 prodotti)
- Src(81 prodotti)
- Syk(37 prodotti)
- Trombina(53 prodotti)
- VDA(2 prodotti)
- VEGFR(249 prodotti)
Mostrare 6 più sottocategorie
Trovati 2061 prodotti di "Angiogenesi"
Ordinare per
Purezza (%)
0
100
|
0
|
50
|
90
|
95
|
100
PROTAC FAK degrader 1
CAS:<p>PROTAC FAK degrader 1 is a selective and potent degrader of focal adhesion kinase (Fak) (IC50 of 6.5 nM).</p>Formula:C47H56F3N9O8S2Purezza:98%Colore e forma:SolidPeso molecolare:996.13PLM-101
<p>PLM-101 is an anticancer compound orally active against acute myeloid leukemia by targeting FLT3 and RET.</p>Formula:C22H22FN5O2Colore e forma:SolidPeso molecolare:407.44ALK-IN-9
CAS:ALK-IN-9 effectively inhibits cell growth with IC50 <0.2 nM for Ba/F3-EML4-ALK, KM12, KG-1.Formula:C20H21FN6O3Colore e forma:SolidPeso molecolare:412.425EGFR-IN-131
EGFR-IN-131 (compound 3a) is an efficacious EGFR inhibitor capable of crossing the blood-brain barrier, with an IC50 value of 272.9 nM. This compound exhibits anti-proliferative activity, induces cellular apoptosis (apoptosis), and causes cell cycle arrest in the G0/G1 phase. Additionally, EGFR-IN-131 reduces the protein expression of p-EGFR.Formula:C26H23FN4O2SColore e forma:SolidPeso molecolare:474.55EGFR-IN-95
<p>EGFR-IN-95 is a derivative of 2,4-diaminonicotinamide. It effectively inhibits the activity of EGFRdel19/T790M/C797S and L858R/T790M/C797S.</p>Formula:C23H28F2N8O3SPeso molecolare:534.19731QL-X-138 HCl
QL-X-138 HCl is a BTK/MNK dual kinase inhibitor with anticancer activity and anti-dengue virus 2 activity that inhibits BTK, MNK1, and MNK2 kinases.Formula:C25H20ClN5O2Purezza:99.25%Colore e forma:SoildPeso molecolare:457.91EGFR/DHFR-IN-1
<p>EGFR/DHFR-IN-1 (Compound 10e) is a dual inhibitor of EGFR and DHFR, with IC50 values of 0.151 µM and 0.541 µM, respectively. It induces cell cycle arrest in the G0-G1 and S phases.</p>Formula:C24H26N4O5S2Peso molecolare:514.13446SNIPER(ABL)-039
CAS:SNIPER(ABL)-039, conjugating Dasatinib (ABL inhibitor) to LCL161 derivative (IAP ligand) with a linker, induces the reduction of BCR-ABL protein with a DC50 ofFormula:C54H68ClN11O9S2Purezza:98%Colore e forma:SolidPeso molecolare:1114.77EGFR-IN-107
<p>EGFR-IN-107 (compound 3r) is an orally active EGFR inhibitor with IC50 values of 0.4333 μM for EGFRWT and 0.0438 μM for EGFRL858R/T790M. It exhibits antiproliferative activity, effectively inhibiting the proliferation of H1975 cells and inducing apoptosis (apoptosis). EGFR-IN-107 is applicable in cancer research.</p>Formula:C34H36FN7O2Peso molecolare:593.29145WDR5 ligand 2
CAS:<p>WDR5ligand 2 is a ligand for WDR5 and can be utilized in the synthesis of PROTAC WDR5degrader 1.</p>Formula:C29H31F3N4O4Colore e forma:SolidPeso molecolare:556.576EGFR/CDK2-IN-4
EGFR/CDK2-IN-4 (compound 4c) is a dual inhibitor targeting EGFR and CDK-2, demonstrating IC50 values of 89.6 nM for EGFR and 165.4 nM for CDK-2.Formula:C24H16N6OS2Purezza:98%Colore e forma:SolidPeso molecolare:468.55FGFR1 inhibitor-2
CAS:FGFR1 inhibitor-2, potent at 4.55 μM IC50 in MDA-MB-231, targets triple-negative breast cancer.Formula:C25H22F5N3O3Colore e forma:SolidPeso molecolare:507.461CS-VIP 8 TFA
CS-VIP 8 TFA is a selective allosteric inhibitor of the WDR5 protein (Ki= 0.008 μM). It induces a conformational change in the MLL1 complex, leading to the dissociation of MLL1 from the complex, thereby inhibiting the MLL1 histone methyltransferase activity and modulating HOX gene expression. CS-VIP 8 TFA shows potential for research in hematological disorders such as leukemia.Formula:C45H53F7N12O9Colore e forma:SolidPeso molecolare:1038.39467GBD-9
CAS:GBD-9, a dual-mechanism degrader, effectively promotes the degradation of BTK and GSPT1 through recruitment of E3 ligase cereblon (CRBN).Formula:C44H47N9O6Purezza:98%Colore e forma:SolidPeso molecolare:797.9PF15 TFA
PF15 TFA, a PROTAC targeting FLT3 kinase and CRBN, exhibits selective degradation of FLT3-ITD with a DC50 of 76.7 nM.Formula:C46H50F3N13O8Purezza:98%Colore e forma:SolidPeso molecolare:969.97DSPE-PEG1000-GE11
<p>DSPE-PEG1000-GE11 is a PEG compound made up of DSPE and an EGFR-targeting peptide (GE11). GE11 is applicable for cancer cells overexpressing EGFR. DSPE-PEG1000-GE11 serves a role in drug delivery.</p>Colore e forma:Odour SolidTYK2 activator-1
TYK2activator-1 (16b) is a TYK2 activator with an EC50 value of 1.78 μM. It inhibits JAK2 and JAK3 with IC50 values of 6.8 μM and 6.3 μM, respectively.Formula:C23H21FN4O2Colore e forma:SolidPeso molecolare:404.16485BCPyr
CAS:BCPyr is a new candidate BTK degrader ( DC 50 = 800 nM).Formula:C58H65F2N11O8Colore e forma:SolidPeso molecolare:1082.224ALK-IN-12
CAS:ALK-IN-12: potent ALK inhibitor (IC50: 0.18 nM), affects IGF1R and InsR (IC50: 20.3/90.6 nM), potential for cancer therapy.Formula:C24H30ClN6O2PColore e forma:SolidPeso molecolare:500.97JAK 3 inhibitor IV
CAS:JAK 3 inhibitor IV (ZM 39923 hydrochloride) is a JAK1/3 inhibitor with pIC50 of 4.4/7.1, almost no activity to JAK2 and modestly potent to EGFR; also found toFormula:C16H19NOPurezza:98%Colore e forma:SolidPeso molecolare:241.33
